Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Bristol-Myers Squibb
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: September 16, 2010
Last updated: November 18, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2017
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)